Neal Bradsher Net Worth

The estimated Net Worth of Neal C Bradsher is at least $75.8 Thousand dollars as of 25 June 2021. Mr. Bradsher owns over 24,720 units of Lineage Cell Therapeutics Inc stock worth over $75,816 and over the last 10 years he sold LCTX stock worth over $0. In addition, he makes $0 as Independent Director at Lineage Cell Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Bradsher LCTX stock SEC Form 4 insiders trading

Neal has made over 2 trades of the Lineage Cell Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 24,720 units of LCTX stock worth $54,384 on 25 June 2021.

The largest trade he's ever made was exercising 24,720 units of Lineage Cell Therapeutics Inc stock on 25 June 2021 worth over $54,384. On average, Neal trades about 3,194 units every 182 days since 2014. As of 25 June 2021 he still owns at least 87,628 units of Lineage Cell Therapeutics Inc stock.

You can see the complete history of Mr. Bradsher stock trades at the bottom of the page.

Neal Bradsher biography

Neal C. Bradsher serves as Independent Director of the Company. Mr. Bradsher has been President of Broadwood Capital, Inc., a private investment firm, since 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher was a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. Mr. Bradsher brings to our Board a wealth of experience in finance, management and corporate governance attained through his investments in other companies, including companies in the pharmaceutical, medical device, medical diagnostics, health care services and health care information systems sectors. He has worked with several health care companies to improve their management and governance. Entities that Mr. Bradsher controls have invested in most of Lineage’s financing transactions over the last several years. Mr. Bradsher is the president of the general partner of Broadwood Partners, L.P., currently our largest shareholder.

How old is Neal Bradsher?

Neal Bradsher is 54, he's been the Independent Director of Lineage Cell Therapeutics Inc since 2009. There are 7 older and 8 younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.

What's Neal Bradsher's mailing address?

Neal's mailing address filed with the SEC is C/O BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK, NY, 10019.

Insiders trading at Lineage Cell Therapeutics Inc

Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley, and Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.

What does Lineage Cell Therapeutics Inc do?

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Complete history of Mr. Bradsher stock trades at Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc executives and stock owners

Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:

• Brandi Roberts,
  Chief Financial Officer
• Brian M. Culley M.A., M.B.A.,
  CEO, Pres & Director
• Brian Culley,
  Chief Executive Officer, Director
• Chase Leavitt,
  General Counsel and Corporate Secretary
• Brandi L. Roberts,
  Consultant
• Angus Russell,
  Independent Director
• Michael Mulroy,
  Independent Director
• Stephen Farrell,
  Independent Director
• Neal Bradsher,
  Independent Director
• Don Bailey,
  Independent Director
• Deborah Andrews,
  Independent Director
• Gary Hogge,
  Senior Vice President of Clinical & Medical Affairs
• Alfred Kingsley,
  Chairman of the Board
• Alexandra Hernandez,
  Sr. Director of Fin. & Controller
• Dr. Rami Skaliter,
  Chief Exec. Officer of Cell Cure Neurosciences Ltd.
• William Annett,
  Pres & CEO of OncoCyte Corp.
• Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
  Sr. VP of Clinical & Medical Affairs
• Dr. François Binette M.Sc., Ph.D.,
  Sr. VP & Global Head of R&D
• George A. Samuel III, J.D.,
  Gen. Counsel & Company Sec.
• Ioana C. Hone,
  Director of Investor Relations
• Kevin L. Cook,
  Chief Financial Officer
• George A. Iii Samuel,
  General Counsel/Secretary
• Anula Jayasuriya,
  
• Dipti Amin,
  
• Neal C Bradsher,
  Director
• Alexandra Hernandez,
  Sr Director Finance/Controller
• Kevin Leon Cook,
  Chief Financial Officer
• Jill Ann Howe,
  Chief Financial Officer